Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

Documenti analoghi

• Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
  di: Chang, Youjin, et al.
  Pubblicazione: (2013)
• Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
  di: Hyun, Dong-gon, et al.
  Pubblicazione: (2020)
• Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
  di: Kwon, Byoung Soo, et al.
  Pubblicazione: (2017)
• Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
  di: Choi, Yun Jung, et al.
  Pubblicazione: (2013)
• Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
  di: Choi, Yun Jung, et al.
  Pubblicazione: (2019)